Lung Cancer Clinical Trials

Showing 801-820 of 2,032 trials

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05816499

This phase Ib/II trial studies how well cadonilimab combined with anlotinib and docetaxel work in treating patients with non-small cell lung cancer that is stage IV or has come back. Cadonilimab, a PD-1/CTLA-4 bispecific antibody, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Anlotinib can regulate tumor microenvironment. Docetaxel was used in standard of care chemotherapy for non-small cell lung cancer, work to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cadonilimab, anlotinib and docetaxel together may work better in treating patients with non-small lung cancer compared to standard of care.

NSCLC Stage IVNSCLC Stage IIIBNSCLC Stage IIIC

Shanghai Chest Hospital50 participantsStarted Feb 2023

Hefei, Anhui, China • Qingdao, Shandong, China • Qingdao, Shandong, China +2 more locations

TERMINATEDPHASE1

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Related Searches

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Trial of Artificial Intelligence for Chest Radiography

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Observation on the Frailty Status of Lung Cancer Patients

Develop and Test the Effects of the 'Computer-Assisted OPD COPSCCP on Early Stage Lung Cancer Patients

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell

Patient-derived Organoids of Lung Cancer to Test Drug Response

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness